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Altering the Tropism of Lentiviral Vectors through Pseudotyping
James Cronin, Xian-Yang Zhang, and Jakob Reiser*
Gene Therapy Program, Louisiana State University Health Sciences Center, New Orleans, LA
70112, USA
Abstract
The host range of retroviral vectors including lentiviral vectors can be expanded or altered by a
process known as pseudotyping. Pseudotyped lentiviral vectors consist of vector particles bearing
glycoproteins (GPs) derived from other enveloped viruses. Such particles possess the tropism of the
virus from which the GP was derived. For example, to exploit the natural neural tropism of rabies
virus, vectors designed to target the central nervous system have been pseudotyped using rabies virus-
derived GPs. Among the first and still most widely used GPs for pseudotyping lentiviral vectors is
the vesicular stomatitis virus GP (VSV-G), due to the very broad tropism and stability of the resulting
pseudotypes. Pseudotypes involving VSV-G have become effectively the standard for evaluating the
efficiency of other pseudotypes. This review samples a few of the more prominent examples from
the ever-expanding list of published lentiviral pseudotypes, noting comparisons made with
pseudotypes involving VSV-G in terms of titer, viral particle stability, toxicity, and host-cell
specificity. Particular attention is paid to publications of successfully targeting a specific organ or
cell types.
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1. EXPANDING THE TROPISM OF LENTIVIRUSES THROUGH
PSEUDOTYPING
One mechanism for expanding the cellular tropism of enveloped viruses is through the
formation of phenotypically mixed particles or pseudotypes, a process that commonly occurs
during viral assembly in cells infected with two or more viruses [Zavada, 1982]. Human
immunodeficiency virus type 1 (HIV-1) has long been known to form pseudotypes by the
incorporation of heterologous GPs through phenotypic mixing, allowing an extension of the
host range of such virions beyond cells that express the CD4 receptor and an appropriate co-
receptor. Several studies have demonstrated that wild type HIV-1 produced in cells infected
with xenotropic murine leukemia virus (MLV) [Canivet, 1990; Lusso, 1990], amphotropic
MLV [Chesebro, 1990; Spector, 1990], or herpes simplex virus [Zhu, 1990] gave rise to
phenotypically mixed virions with an expanded host range, suggesting that pseudotyped virions
had been produced. Phenotypic mixing of viral GPs has also been shown to occur between
HIV-1 and vesicular stomatitis virus in coinfected cell cultures [Zhu, 1990]. These early
observations were key to the subsequent design of HIV-1-based lentiviral vectors bearing
heterologous GPs.
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2. PSEUDOTYPED HIV-1 VECTOR PARTICLES
Page et al. [Page, 1990] were the first to design and test HIV-1-based vector particles harboring
a heterologous GP. In this study, the HIV-1 genome was rendered replication defective by
replacing the GP-encoding gp160 sequence with a guanine-phosphoribosyl transferase (gpt)
gene driven by the Simian virus 40 (SV40) early promoter. Transient cotransfection of monkey
COS-7 cells with this GP-deleted vector and an expression plasmid encoding an amphotropic
MLV GP resulted in packaging of the HIV-gpt vector genome into infectious virions. Upon
infection of susceptible cells, the gpt gene was transmitted and expressed, allowing transduced
cells to be selected in media containing mycophenolic acid [Page, 1990]. Landau et al. [Landau,
1991] subsequently demonstrated that expression of other GPs including those of the ecotropic
MLV and human T-cell leukemia virus type I (HTLV-I) in cells transfected with the HIV-gpt
vector resulted in the production of vector pseudotypes capable of infecting murine and human
cells with titers reaching 105 colony forming units per ml following mycophenolic acid
selection.
3. EARLY LENTIVIRAL VECTORS AND THE RISE OF VSV-G PSEUDOTYPES
These early observations were confirmed and extended in 1996 by results reported
independently by three groups showing that VSV-G was also efficiently incorporated into
HIV-1 virions [Akkina, 1996; Naldini, 1996; Reiser, 1996]. Lentiviral vectors pseudotyped
with VSV-G presented significant advantages in that VSV-G appears to interact with a
ubiquitous cellular “receptor” on cells, giving the vector a broad host-cell range. The receptor
for VSV has long been thought to be a ubiquitous membrane lipid, phosphatidylserine
[Schlegel, 1983]. However, recent experimental evidence has indicated that phosphatidylserine
is not the cell surface receptor for VSV, although it may be involved in a postbinding step of
virus entry [Coil, 2004]. VSV-G pseudotyping also confers high vector particle stability,
allowing for concentration by ultracentrifugation [Burns, 1993; Bartz, 1996]. Perhaps the most
significant shortcoming for VSV-G is that it is toxic to cells if expressed constitutively. The
use of tetracycline-regulatable promoters has alleviated this problem and facilitated the
generation of stable cell lines expressing VSV-G [Ory, 1996]. Another potential drawback for
in vivo applications is that VSV-G pseudotypes are inactivated by human serum complement
[DePolo, 2000]. This problem can be bypassed by using polyethylene glycol-modified
(PEGylated) VSV-G pseudotypes. Covalent modification of VSV-G pseudotyped HIV-1
vector particles using monomethoxypoly(ethylene) reduced the rate of vector inactivation by
a factor of 1,000 and significantly enhanced transduction efficiency in the bone marrow and
spleen after systemic administration of the virus [Croyle, 2004].
To date, VSV-G remains the most popular GP for pseudotyping HIV-1-based vectors as well
as other lentiviral vectors including vectors based on HIV-2 [Poeschla, 1998a] and on simian
immunodeficiency virus (SIV) [Nakajima, 2000; Negre, 2000; Schnell, 2000]. Vectors based
on nonprimate lentiviruses include feline immunodeficiency virus (FIV) [Poeschla, 1998b],
equine infectious anemia virus (EIAV) [Mitrophanous, 1999], bovine immunodeficiency virus
(BIV) [Berkowitz, 2001a], Jembrana disease virus (JDV) [Metharom, 2000], visna virus (VV)
[Berkowitz, 2001b], and caprine arthritis encephalitis virus (CAEV) [Mselli-Lakhal, 2000]
(Table 1).
4. LENTIVIRAL PSEUDOTYPES INVOLVING ALTERNATIVE
GLYCOPROTEINS
There is an ever-growing list of alternative GPs for pseudotyping lentiviral vectors, each with
specific advantages and disadvantages. While space limitations preclude an exhaustive
description of all pseudotypes, this review will survey some of the more prominent examples
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in the recent literature. Other emerging pseudotypes are referred to in Table 1. The widespread
use of VSV-G to pseudotype lentiviral vectors has made this GP in effect the standard against
which the usefulness of other viral GPs to form pseudotypes are compared. Comparison of
pseudotype efficiency inevitably means comparing vector titers on cell lines in vitro. This
brings up two important issues: (i) Techniques to determine lentiviral vector titers, and (ii) Cell
lines chosen for titration of such vectors. There are different measures used to determine
lentiviral vector titers. Some of them are based on the number of vector particles present in a
virus stock while others are derived from the number of proviral copies in transduced target
cells. Virus particle numbers can be determined using real-time PCR based on strong-stop
cDNA present in virions [Scherr, 2001]. Alternatively, the amount of virus proteins present in
virus cores such as p24 Gag are determined by ELISA to arrive at relative particle titers [Logan,
2004]. Functional titration assays are based on vector-encoded reporter gene expression. For
example, vectors encoding green fluorescent protein (GFP) have been titrated using FACS
analysis [Zhang, 2002]. For vectors that do not contain a reporter gene, proviral DNA copy
numbers determined by real-time PCR using DNA extracted from transduced cells have been
used to determine titers [Sastry, 2002]. As each of these methods produces different results, a
reader of the literature must pay close attention to which titration method was used. Also
significant for titration is the cell line used as receptors for a given GP may vary from cell line
to cell line, possibly producing a falsely depressed titer. Frequently, a given cell line (such as
HeLa or 293 cells) is chosen because it is considered generally permissive to infection rather
than representing the natural tropism of the virus from which the GP was derived. Additionally,
results produced with a given cell line or type of cell in vitro do not always translate into
comparable results in vivo due to factors such as complement-mediated inactivation of vectors.
Careful attention must also be paid to the given virus strain from which the GP was derived as
this may also be a source of confusion and conflicting results. For example, considerable
differences in the brain transduction patterns were demonstrated between two related
lyssavirus-derived GPs. Transduction of the mouse striatum by HIV-1 vectors pseudotyped
with the GP derived from a Mokola virus originally isolated from a cat in Zimbabwe (MokZIM)
[Bourhy, 1989] was inefficient [Desmaris, 2001], while HIV-1 vectors bearing a Mokola virus
GP obtained from an Ethiopian Mokola virus isolate (MokETH) [Mebatsion, 1995] revealed
robust transduction [Watson, 2002].
The following is an overview of prominent examples of lentivirus pseudotypes that have
appeared in the literature. Additional examples that are not discussed in the text are referred
to in Tables 1 and 2.
4.1. Pseudotypes Bearing Lyssavirus-derived GPs
The capacity of lentiviral vectors to form pseudotypes with lyssavirus GPs was investigated
early on with a view toward designing neurotropic lentiviral vectors. The genus Lyssavirus is
part of the Rhabdoviridae family and includes the classical rabies viruses and rabies-related
viruses including Mokola virus [Badrane, 2001]. Rabies virus (RV), the prototype of the genus
Lyssavirus, is an enveloped negative-strand RNA virus encoding five structural proteins
including the transmembrane GP. The transmembrane GPs of lyssaviruses appear to exhibit a
similar overall structure; however, considerable antigenic differences were noted between RV
and rabies-related viruses by using anti-GP monoclonal antibodies. Rabies is a disease of the
CNS and neuroinvasiveness is the major defining characteristic of a classical RV infection.
Mochizuki et al. [Mochizuki, 1998] were the first to describe robust pseudotyping of HIV-1
lentiviral vectors using lyssavirus-derived GPs including those of the rabies virus strain
RabSADB19 [Conzelmann, 1990] and the Mokola virus MokETH strain [Mebatsion, 1995].
The Lyssavirus pseudotypes were compared to VSV-G pseudotypes by analyzing
unconcentrated virus stocks on human osteosarcoma (HOS) cells and on Rat-2 fibroblasts. The
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lyssavirus GPs produced identical titers, which were 5 times lower than those of VSV-G
pseudotypes on HOS cells and 4 times lower on Rat-2 cells. Shortly thereafter, EIAV vectors
were successfully pseudotyped with a RV GP [Mitrophanous, 1999] (the source of the rabies
GP used for pseudotyping was not revealed).
4.1.1. Neurotropism of Lentiviral Vectors Pseudotyped with Lyssavirus GPs—
Once successful pseudotyping of lentiviral vectors with lyssavirus-derived GPs had been
demonstrated, interest was focused on assessing the neurotropism of such pseudotypes.
Desmaris et al. [Desmaris, 2001] initially tested the infectivity of HIV-1 vector pseudotypes
bearing a Mokola virus GP (MokZIM strain) or VSV-G. The in vivo tropism of the two
pseudotypes was tested by injecting vector particles encoding β-galactosidase (β-gal) into the
striatum. The two pseudotypes produced comparable numbers of β-gal expressing cells, and
co-labeling for cell-type markers indicated that both vectors had primarily transduced neurons.
Watson et al. [Watson, 2002] described a similar analysis involving HIV-1 vectors
pseudotyped with the MokETH GP. Intrastriatal injection of such pseudotypes in the mouse
also resulted in extensive transgene expression along the corpus callosum and external capsule.
Transduction by pseudotypes bearing the MokETH GP in both the striatum and the white matter
was considerably more extensive than that observed with pseudotypes involving VSV-G.
Mokola pseudotypes however were not transported along projections from the striatum to the
substantia nigra [Watson, 2002]. To assess whether lentiviral vector particles pseudotyped with
lyssavirus GPs gain access to the CNS by retrograde transport, pseudotyped HIV-1 virions
were either injected into the nasal cavity or injected into limb muscles of rats. Both VSV-G
and MokZIM pseudotypes produced β-gal-expressing neurons in the olfactory bulb after nasal
injection, but neither produced β-gal-positive motor neurons in the spine [Desmaris, 2001].
The investigators concluded that VSV-G and MokZIM pseudotypes were of comparable
efficiency in retrograde axonal transport, but that neither was taken up at the neuromuscular
junction. In a related study, EIAV-based vectors pseudotyped with the GPs derived from the
RV RabERA strain [Sacramento, 1992] or from VSV-G were injected into the striatum to
compare the spread of the virus as judged from the number and distribution of transgene-
expressing cells [Mazarakis, 2001]. After injection of VSV-G pseudotypes, some 30,000 β-
gal-positive cells were found in the striatum. At a comparable titer, RabERA pseudotypes
produced 32,000 β-gal-positive cells in the striatum plus 14,800 cells in the thalamus along
with 3000 cells in the substantia nigra, indicating both retrograde and anterograde transport.
The GPs of the rabies RabCVS [Sacramento, 1992] and RabERA strains produced similar
transgene expression patterns in distal brain areas after striatal injection of EIAV vectors
[Wong, 2004]. However, a change from arginine to glutamine at amino acid 333 of the RabERA
GP resulted in weaker transduction of the caudate putamen. Interestingly, there was no
retrograde transport of vectors bearing the mutated RabERA GP to areas such as the thalamus.
This suggests that this single mutation in the viral GP was sufficient to abolish the virus'
retrograde transport characteristics [Wong, 2004]. Instraspinal injections of EIAV vectors
pseudotyped with the RabERA GP have likewise demonstrated spread of transgene expression
along nerve tracts. This was not seen after injection of VSV-G pseudotypes [Mazarakis,
2001].
4.1.2. Lentiviral Vectors Pseudotyped with Lyssavirus GPs to Treat Motor
Neuron Disease—Of potential clinical importance, intramuscular injection of EIAV vectors
pseudotyped with RV GPs resulted in transgene expression in spinal motor neurons. Retrograde
transport of lentiviral vectors from peripheral muscle to spinal motor neurons has been used
to demonstrate a therapeutic effect in an animal model of familial amyotrophic lateral sclerosis
(ALS) [Azzouz, 2004b]. This model is based on SOD1G93A mice which have a mutation in
the SOD1 gene and experience severe motor neuron degeneration comparable to that seen in
human ALS. EIAV-based vectors encoding vascular endothelial growth factor (VEGF) were
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pseudotyped with the RabERA GP and injected into various muscle groups of 3 week-old
SOD1G93A mice. Animals that were injected with a control vector were severely impaired by
100 days of age, while comparable impairment in animals that received the VEGF vector was
delayed until a month later. EIAV/VEGF vector treatment also extended lifespan of these
animals by 30%. Clinical markers such as rotarod performance were also improved with EIAV/
VEGF vector treatment. In a related study, EAIV vectors expressing either a marker gene or
the human survival motor neuron (SMN) cDNA and pseudotyped with the RabERA GP were
injected into various muscles of spinal muscle atrophy (SMA) mice. Retrograde transport of
the virus to spinal motor neurons was confirmed by marker gene expression. Compared to
untreated controls, SMN-vector treatment restored SMN protein levels in motor neurons,
reduced motor neuron death, and increased the life expectancy by an average of 3 and 5 days
(20% and 38%) [Azzouz, 2004a]. These examples demonstrate the capacity of lentivirus
vectors pseudotyped with RV GPs to deliver therapeutic genes to otherwise inaccessible
neurons by exploiting the lyssavirus' ability to induce retrograde transport along axons.
4.2. Pseudotyped Lentiviral Vectors Bearing Lymphocytic Choriomeningitis Virus GPs
4.2.1. Pseudotype Formation Using Lymphocytic Choriomeningitis Virus GPs—
MLV-based retroviral vectors pseudotyped with the lymphocytic choriomeningitis virus
(LCMV) GP have been shown to efficiently transduce cells from different tissues relevant to
gene therapy including fibroblasts, epithelial cells, hematopoietic cells, as well as hepatoma,
neuroblastoma and glioma cell lines [Miletic, 1999]. Successful transduction involving
pseudotypes containing the LCMV-WE GP [Romanowski, 1985] was observed in cell lines
derived from various species of human, mouse, hamster, or dog origin. LCMV is a
noncytopathic arenavirus, which infects a broad range of different cell types. The LCMV GPs
are synthesized as a 74-kDa precursor protein, GP-C, and then cleaved into a 35-kDa
transmembrane protein, GP-2, and an external 44-kDa protein, GP-1. Alpha-dystroglycan, a
cellular receptor for LCMV [Cao, 1998; Smelt, 2001], is a dystrophin-associated GP that
connects the cytoskeleton with the extracellular matrix, and is widely expressed in most tissues.
Pseudotyping of HIV-1-based lentiviral vectors with the GP derived from the LCMV
Armstrong 53b strain (LCMV-Arm53b, [Salvato, 1988]) was first reported in 2001
[Christodoulopoulos, 2001]. The titers obtained with such pseudotypes on 293T cells were at
least two logs below those observed with vectors pseudotyped with the amphotropic MLV GP
or VSV-G. Interestingly, LCMV-pseudotyped lentiviral vectors containing the GP of the
LCMV-WE strain revealed vector titers similar to those obtained with pseudotypes containing
the amphotropic MLV GP or VSV-G [Beyer, 2002].
4.2.2. Applications of LCMV Pseudotypes—A number of applications involving
lentiviral vectors pseudotyped with LCMV GPs have been described. The following is an
overview of these applications. Loss of insulin-secreting pancreatic islet cells leads to insulin-
dependent diabetes. As diabetes is a significant public health problem, genetic manipulation
of islet cells aimed at preventing their destruction is important for both clinical applications
and understanding islet cell biology. Kobinger et al. [Kobinger, 2004] evaluated the ability of
a HIV-1-based lentiviral vector pseudotyped with various viral GPs to target human islets ex
vivo, with the goal of improving transduction efficiency while minimizing toxicity. LCMV-
pseudotyped vectors transduced insulin-secreting beta cells with the highest efficiency.
Moreover, toxicity associated with transduction of islets was found to be lower with LCMV-
WE-pseudotyped vectors than with VSV-G-pseudotyped vectors, the second most efficient
pseudotype for islet transduction.
A reduced toxic response to LCMV pseudotypes compared to VSV-G pseudotypes was also
found in the liver following portal vein injection of HIV-1-based vectors encoding human
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blood-clotting factor VIII (hFVIII) [Park, 2003]. Transduction of hemophilia A mice with
hFVIII expressing lentiviral vectors resulted in transient correction of the bleeding diathesis
phenotype. Moreover, the use of vectors pseudotyped with the LCMV-WE GP resulted in
similar circulating levels of hFVIII. Similar doses of LCMV-pseudotyped lentiviral vectors
resulted in minimal systemic or hepatic injury compared to VSV-G pseudotypes. Taken
together, these studies demonstrate the importance of using alternative pseudotypes, such as
LCMV, to minimize adverse vector effects in vitro and in vivo.
There is increasing interest in developing gene therapy strategies for malignant gliomas, which
are the most frequent primary brain tumors, but have a poor prognosis with current treatments.
Work reported by Beyer et al. [Beyer, 2002] showed that LCMV-WE pseudotypes were able
to transduce human glioma and neuroblastoma cell lines, as well human primary glioma cells
derived from resected human gliomas. In a related study, Miletic et al. [Miletic, 2004] assessed
the transduction efficiencies of HIV-1 vectors pseudotyped with the LCMV-WE GP or VSV-
G in malignant glioma cells and normal brain cells both in vitro and in vivo. In vitro, LCMV-
WE pseudotypes transduced almost exclusively astrocytes, whereas VSV-G pseudotypes
transduced neurons as well as astrocytes. In an in vivo glial tumor model based on rats carrying
intracerebral grafts of rat 9L gliosarcoma cells, LCMV-WE pseudotypes revealed efficient
transduction of solid glioma parts and specific transduction of infiltrating tumor cells. In
contrast, VSV-G-pseudotyped lentiviral vectors transduced only a few tumor cells in solid
tumor parts and transduced mostly neurons surrounding the tumors. Similar results were
reported by Steffens et al. [Steffens, 2004]. These authors compared eight different lentivirus
pseudotypes regarding their efficiencies to transduce neuronal and glial tumor cell lines.
Pseudotypes involving the GPs of human foamy virus, RV (RabSADB19 strain), Mokola
(MokETH strain) or amphotropic MLV displayed the highest transduction efficiency in
neuroblastoma cells, whereas pseudotypes involving the LCMV-Arm53b GP resulted in the
highest transduction efficiency in gliomas.
In a recent report, an FIV vector expressing β-gal and pseudotyped with the LCMV-WE GP
was injected into postnatal mouse brain striatum to determine neural cell-type transduction
[Stein, 2005]. β-gal-expressing cells included astrocytes in the striatum and in the
subventricular zone (SVZ), neuroblasts along the rostral migratory stream, and neurons in the
olfactory bulb. This pattern was suggestive of transduction of neural stem/progenitor cells that
reside in the SVZ and continually generate olfactory bulb neurons. Thus, FIV/LCMV-WE
pseudotypes are potentially useful for targeting neural stem/progenitor cells in vivo. Taken
together, these results demonstrate that targeted transduction in the CNS can be achieved using
specific pseudotypes.
4.3. Lentivirus Pseudotypes Bearing Alphavirus GPs
Alphaviruses exhibit a wide cellular tropism that includes important gene therapy targets such
as antigen-presenting cells, neurons, and muscle cells. Alphaviruses belong to the family
Togaviridae and are found in insects, reptiles, birds, and mammals. Although it remains to be
determined as to what molecules act as cellular receptors for these viruses, it has been suggested
that several receptors or several receptor-coreceptor combinations are involved in virus entry.
The main part of the viral GP complex consists of heterodimers of the E1 and E2 GPs that are
further organized into trimers. A total of 80 of these trimeric spikes are distributed on the outer
surface of the virion. The E2 GP most likely mediates interactions with target cell receptors,
whereas E1 is thought to mediate fusion. Several reports describing successful pseudotyping
of lentiviral vectors involving the Ross River virus (RRV), Semliki Forest virus (SFV) and
Sindbis virus GPs have appeared in the literature.
Cronin et al. Page 6













4.3.1. Lentiviral Vectors Pseudotyped with the RRV and SFV GPs—Kang et al.
[Kang, 2002] were the first to describe lentivirus pseudotypes involving alphavirus GPs. These
authors examined the in vivo gene transfer efficiency and tissue or cell tropism of a FIV-based
lentiviral vector pseudotyped with the GPs derived from RRV. RRV GPs were efficiently
incorporated into FIV virions, generating preparations of FIV vectors, which after
concentration attained high titers. After systemic administration, RRV-pseudotyped FIV
vectors (RRV/FIV) predominantly transduced the liver of recipient mice. Transduction
efficiency in the liver with the RRV/FIV was about 20-fold higher than that achieved with a
VSV-G pseudotype. Moreover, in comparison to VSV-G, the RRV GPs caused less
cytotoxicity. Although hepatocytes were the main liver cell type transduced, nonhepatocytes
(mainly Kupffer cells) were also transduced. After injection into the brain, RRV/FIV
preferentially transduced neuroglial cells (astrocytes and oligodendrocytes). In contrast to the
VSV-G protein that targets predominantly neurons, <10% of the brain cells transduced with
the RRV pseudotyped vector were neurons.
Kahl et al. [Kahl, 2004] subsequently showed that the GPs derived from RRV and SFV can
pseudotype HIV-1-derived lentivirus vectors and that both RRV and SFV GPs considerably
expanded the host range of these vectors. Also, such pseudotypes could be efficiently
concentrated by ultracentrifugation. A systematic analysis comparing the alphaviral GPs to
VSV-G revealed that lentivirus vectors incorporated RRV GPs with an efficiency comparable
to that of VSV-G. Both pseudotypes had comparable physical titers as judged by quantitative
RT-PCR amplification of vector RNA. However, infectious titers with the RRV pseudotype
were lower than with VSV-G as determined by FACS analysis of GFP expression in transduced
cells. However, incorporation of SFV GPs into lentivirus vector was less efficient, leading to
significantly decreased physical and infectious titers.
In a recent report by Kahl et al. [Kahl, 2005] the transduction of hematopoietic cells using
RRV-pseudotyped lentiviral was investigated. RRV-mediated transduction of human CD34+
cord blood cells and progenitors was very inefficient, even at multiplicities of infection of 100.
Inefficient transduction was also observed in a variety of hematopoietic cell lines. However,
exposing the monocytic cell line THP-1 to 12-O-Tetradecanoylphorbol-13-acetate (TPA), a
very potent activator of macrophage differentiation, induced a more than 10-fold increase in
transduction. The uniquely restricted host range of RRV-pseudotyped vectors in hematopoietic
cells may aid in the design of novel cell-selective transduction strategies.
Sustained production of lentiviral vectors pseudotyped with RRV and SFV from stable
packaging cell lines was reported by Strang et al. [Strang, 2005]. Cell clones producing high-
titer RRV pseudotypes were stable for at least 5 months while clones producing SFV
pseudotypes produced relatively low titers. RRV pseudotypes were found to display a number
of characteristics that are attractive, including resistance to inactivation by heat-labile
components in fresh human sera and thermostability at 37°C. Upon concentration by
ultracentrifugation, vector stocks with titers up to 6 × 107 transducing units (TU)/ml were
obtained.
4.3.2. Lentiviral Vectors Pseudotyped with Sindbis Virus GPs—One strategy for
cell-specific targeting has been the insertion of cell-specific ligands including single chain
antibodies into the viral GP, or to bridge the virus and target cell using a ligand or antibody
bridge. Morizono et al. [Morizono, 2001] having shown that the GP of Sindbis virus is able to
pseudotype oncoretroviruses and lentiviruses, reported an oncoretroviral and lentiviral gene-
targeting system based on antibody-mediated specific binding of a modified chimeric Sindbis
virus GP. The Fc-binding domain (ZZ domain) of protein A was inserted into the Sindbis E2
protein, to produce the ZZ SINDBIS GP. They also showed that monoclonal antibodies directed
to cell-surface antigens can be used to redirect the target specificity of these vectors when
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pseudotyped with the modified Sindbis virus GP. Of particular note, the vectors maintained
high viral titers, which could be further increased by simple ultracentrifugation. Intravenous
injection of such pseudotypes into mice resulted in high levels of transduction in liver and
spleen cells. An exciting recent report from the same lab [Morizono, 2005] documented
successful targeting in a living animal through intravenous injection of a lentiviral vector
pseudotyped with a modified chimeric Sindbis virus GP. The modified GP (termed m168)
contained a ZZ domain and carried a 4 aa deletion in E3 and two separate point mutations
within E2. m168 pseudotypes were found to display a high targeting specificity and, unlike
other pseudotypes, had low nonspecific infectivity in liver and spleen. A mouse cancer model
of metastatic melanoma was used to test intravenous targeting with m168. Human P-GP was
ectopically expressed on the surface of melanoma cells and targeted by the m168 pseudotyped
lentiviral vector conjugated with antibody specific for P-glycoprotein. m168 pseudotypes
successfully targeted metastatic melanoma cells growing in the lung after systemic
administration by tail vein injection. Further development of this targeting technology may
result in applications not only for cancers but also for genetic, infectious and immune diseases.
4.4. Pseudotypes Bearing Filovirus GPs
4.4.1. Pseudotype Formation Using Filovirus GPs—In 2000 Chan et al. [Chan,
2000] described the successful pseudotyping of HIV-1 vectors using Marburg virus and Ebola
Zaire (EboZ) virus-derived virion GPs. The folate receptor-alpha was soon thereafter identified
as a cofactor for cellular entry by Marburg and Ebola viruses [Chan, 2001]. The Ebola and
Marburg filoviruses are highly pathogenic viruses that induce hemorrhagic fevers in humans
and nonhuman primates. Of the four identified strains of Ebola virus, Zaire, Ivory Coast, Sudan,
and Reston, the Zaire strain induces the highest death rates in humans, while the Reston strain
has not caused fatal disease in humans. Mononuclear phagocytic cells form the primary targets
for filovirus replication, while endothelial cells serve as secondary targets. The GP-encoding
region of Ebola virus gives rise to two products, a nonstructural secreted form of the GP, sGP,
encoded by the predominant transcript (80%), and the virion GP, the result of RNA editing
during formation of the message (20%).
4.4.2. In Vivo Tropism of Lentiviral Vectors Pseudotyped with the EboZ GP—The
in vivo tropism of lentiviral vectors pseudotyped with EboZ as compared to VSV-G was tested
by in utero intramuscular and intrahepatic injections [MacKenzie, 2002]. Injected animals were
harvested at time points between 5 days and 9 months following injection and detailed
histologic assessments were performed. The efficiency and distribution of transduction after
in utero administration was highly dependent upon the route of administration and the vector
pseudotype used. Biodistribution studies showed widespread distribution of vector sequences
in multiple tissues, albeit at very low levels, and transduced cells were found in significant
numbers only in liver, heart, and muscle. Overall, vectors pseudotyped with VSV-G were the
most efficient in transducing hepatocytes, whereas vectors pseudotyped with the MokETH and
EboZ GPs were more efficient in transducing myocytes. Transduction of cardiomyocytes was
observed after both intramuscular and intrahepatic injection of all three vectors. EboZ-
pseudotyped vectors injected into muscle in utero were found to transduce muscle satellite or
stem cells. Examination of transgene expression in regenerated muscle after injury showed that
the newly generated tissue had originated from transduced satellite cells [MacKenzie, 2005].
Direct brain injection of EboZ/HIV pseudotypes in adult mice failed to transduce cells in the
brain [Watson, 2002] and EboZ pseudotypes were also unable to transduce oligodendrocyte
cultures. This may be due to the lack of the proper receptor since folate receptor-alpha
expression was found to be low in the CNS.
4.4.3. Airway Applications Involving Lentiviral Vectors Pseudotyped with
Filovirus GPs—The application of gene delivery strategies as a treatment for cystic fibrosis
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is limited by poor gene transfer efficiency with vectors applied to the apical surface of airway
epithelia. To overcome this limitation, Kobinger et al. [Kobinger, 2001] carried out a
systematic analysis of lentivirus vector pseudotypes to stably transduce airway epithelia in
vivo. To do this, HIV-1-based vectors pseudotyped with the amphotropic MLV, Mokola
(MokETH), HA (influenza-hemagglutinin), EboZ and Ebola-Reston (EboR) GPs were applied
apically and basolaterally to cultures of airway epithelial cells. EboR and HA pseudotypes
were completely ineffective, and only EboZ pseudotypes were able to efficiently transduce
after apical application. In the same study, human tracheal explants were incubated with EboZ
and VSV-G pseudotypes. VSV-G was largely ineffective while the EboZ pseudotype
efficiently transduced airway epithelium. EboZ pseudotypes were similarly more effective than
VSV-G pseudotypes in an in vivo test in mice receiving vector pseudotypes intratracheally.
Sinn et al. [Sinn, 2003] found that polarized human airway epithelia expressed abundant folate
receptor alpha on their apical surface. In an attempt to target these apical receptors, FIV-based
vectors were pseudotyped using GPs derived from the Marburg and EboZ viruses. Deletion of
a heavily O-glycosylated extracellular domain of the EboZ GP including amino acids 309 to
489 resulted in the EboZΔO GP variant. The titer of concentrated FIV vector stocks
pseudotyped with EboZΔO was increased some 74-fold. Both EboZ/FIV and EboZΔO/FIV
transduced airway epithelia from the apical surface at greater efficiency than from the
basolateral surface. In contrast, VSV-G/FIV transduced the basolateral surface more efficiently
than the apical one. In addition, the EboZ GP contains a mucin-rich region that was
demonstrated to reduce expression of cellular adhesion molecules and induce cytotoxic effects
to endothelial cells in vitro and in vivo. Medina et al. [Medina, 2003] developed several mutant
EboZ GPs that contained deletions corresponding to the mucin-rich domain. Lentiviral vectors
pseudotyped with these mutant GPs possessed higher titers compared to vectors pseudotyped
with the unmodified EboZ GP. Also, they resulted in more efficient gene transfer in vivo.
4.5. Lentiviral Vectors Bearing Retrovirus GPs
4.5.1. Pseudotype Formation Using Gammaretrovirus GPs—A variety of different
envelope GPs derived from gammaretroviruses were shown to pseudotype lentivirus vectors.
The GPs included those derived from the ecotropic MLV [Landau, 1991; Reiser, 1996],
amphotropic 4070A MLV [Reiser, 1996], 10A1 MLV [Stitz, 2000; Christodoulopoulos,
2001], xenotropic NZB MLV and that of the polytropic mink cell focus-forming virus
[Christodoulopoulos, 2001]. Other GPs included that of the gibbon ape leukemia virus (GALV)
[Stitz, 2000; Christodoulopoulos, 2001] and the RD114 GP [Hanawa, 2002; Sandrin, 2002;
Zhang, 2004]. The titers of lentiviral vectors pseudotyped with these GPs were usually lower
than those observed with VSV-G. However these pseudotypes were stable and retained full
infectivity during concentration by ultrafiltration or ultracentrifugation [Reiser, 1996; Reiser,
2000; Hanawa, 2002; Sena-Esteves, 2004].
4.5.2. Lentiviral Vectors Pseudotyped with Gammaretrovirus GPs in
Applications Involving CD34+ Hematopoietic Progenitor Cells, T Lymphocytes,
and Mesenchymal Stem Cells—Hanawa et al. [Hanawa, 2002] showed that HIV-1 vectors
pseudotyped with the RD114 and amphotropic MLV GPs were more efficient than VSV-G
pseudotypes at transducing human cord blood-derived CD34+ cells and clonogenic
progenitors. In addition, amphotropic MLV pseudotypes transduced cytokine-mobilized,
human peripheral blood CD34+ cells capable of establishing hematopoiesis in
immunodeficient mice more efficiently than VSV-G pseudotypes. Work reported by
Muhlebach et al. [Muhlebach, 2003] revealed that MLV vectors pseudotyped with the MLV
10A1 and the GALV GPs resulted in efficient transduction of preactivated human primary T
lymphocytes while pseudotypes bearing the amphotropic MLV, RD114 and VSV-G GPs were
less efficient. In contrast, HIV-1 vectors pseudotyped with the same GPs transduced
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preactivated T lymphocytes with similar efficiencies. This may reflect differences in the half-
lives of lentiviral vector pseudotypes compared to MLV pseudotypes containing the same GPs.
In a study involving pseudotyped SIVmac251-based vectors, Sandrin et al. [Sandrin, 2002]
showed that GALV and RD114 pseudotypes displayed a much reduced infectivity relative to
vectors pseudotyped with the VSV-G, LCMV and amphotropic 4070A MLV GPs.
Interestingly, SIV vectors pseudotypes bearing chimeric GPs with the extracellular and
transmembrane domains of GALV or RD114 fused to the cytoplasmic tail of the amphotropic
4070A MLV GP, augmented the transduction efficiency of such pseudotypes in human and
macaque primary blood lymphocytes and CD34+ cells. This may have been caused by changes
in the intracellular trafficking and assembly of the GPs on viral cores due to changes of the
cytoplasmic tails [Sandrin, 2004]. Similar results were reported by Zhang et al. [Zhang,
2004] who showed that transduction efficiencies in human mesenchymal stem cells (MSCs)
with HIV-1 vectors pseudotyped with the unmodified RD114 GP were 1 to 2 orders of
magnitude below those observed with VSV-G pseudotypes. However, HIV-1 vectors
pseudotyped with a chimeric RD114 GP harboring an amphotropic 4070A MLV cytoplasmic
tail revealed about 15-fold higher titers relative to the unmodified RD114 GP.
4.6. Lentiviral Vector Pseudotypes Containing the Baculovirus GP64 GP
Baculoviruses, which are used as biopesticides, primarily infect members of the Lepidopteran
family. It was found that recombinant baculoviruses are able to deliver transgenes into
mammalian cells provided that they are controlled by a promoter that is active in mammalian
cells [Ghosh, 2002]. GP64 is the major baculovirus GP and interest has recently been directed
towards using the GP64 GP to pseudotype lentiviral vectors [Kumar, 2003]. GP64-
pseudotyped HIV-1 vectors tolerated ultracentrifugation well and efficiently transduced
various cell types although GP64 pseudotypes showed a more restricted tropism than VSV-G
pseudotypes, with an especially poor ability to transduce hematopoietic cell types including
dendritic cells [Schauber, 2004]. More notably, GP64 expression was not cytotoxic to host
cells. Thus, derivation of a permanent cell line constitutively expressing GP64 at high levels
over many passages was successful [Kumar, 2003]. Lentiviral vectors pseudotyped with the
baculovirus GP64 were found to be inactivated by human complement [Schauber, 2004]. In
animal sera, the vectors were mostly resistant to inactivation by rodent complement, whereas
canine complement caused a moderate reduction in titer [Schauber-Plewa, 2005]. Human
complement-resistant pseudotyped HIV-1 vector particles were subsequently produced
through incorporation of complement regulatory proteins. Co-display of decay accelerating
factor (DAF)/CD55 or of a GP64-DAF fusion protein stabilized GP64-bearing vector particles
against inactivation by human and nonhuman primate serum [Guibinga, 2005; Schauber-
Plewa, 2005].
5. METHODS TO PRODUCE, CONCENTRATE AND PURIFY LENTIVIRAL
VECTOR PSEUDOTYPES
5.1. Production of Lentiviral Vectors Using Packaging Cell Lines
To facilitate large-scale reproducible lentiviral vector production, a number of groups have
established lentivirus packaging cell lines. Several of the proteins required to assemble
lentiviral vector particles including VSV-G [Burns, 1993], HIV-1 Vpr [Bartz, 1996], Tat [Li,
1995], Rev [Miyazaki, 1995], and protease [Konvalinka, 1995] are detrimental to mammalian
cells when overexpressed. Thus, for stable production of HIV-1 vectors pseudotyped with
VSV-G, 293-based cell lines allowing conditional production of virus-encoded proteins and
VSV-G using tetracycline regulated promoters were generated that yielded titers up to 106 TU/
ml [Kafri, 1999; Klages, 2000; Farson, 2001; Xu, 2001]. Inducible cell lines for the production
of SIV vectors pseudotyped with VSV-G were also established [Kuate, 2002]. This was
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achieved with expression plasmids containing a codon-optimized gag-pol coding region of SIV
and the VSV-G coding region under the control of a ponasterone-inducible promoter. Vector
titers at around 105 TU/ml were obtained.
To rapidly and reproducibly generate high-titer HIV-1 vector pseudotypes, Ikeda et al. [Ikeda,
2003] generated stable cell lines expressing GPs of gammaretroviruses including the
amphotropic 4070A MLV GP, the RD114 GP with an HIV protease site introduced at the R-
peptide cleavage site (RDpro), or the GALV glycoprotein with an MLV cytoplasmic tail. In
concert with a codon-optimized HIV-1 gagpol coding region, these producer cells could make
lentiviral pseudotyped particles with titers up to 107 TU/ml (20 TU/cell/day) for at least three
months in culture. Compared to vectors pseudotyped with VSV-G, the gammaretrovirus
pseudotypes were relatively stable at 37°C and were resistant to inactivation by freeze/thaw
cycling or incubation with human sera [Strang, 2004]. More recently, Strang et al. [Strang,
2005] established stable producer cell lines for HIV-1 vectors pseudotyped with the alphavirus
RRV and SFV E2E1 GPs. Stable clones produced high-titer RRV-pseudotyped HIV-1 vectors
for at least 5 months. Clones producing SFV pseudotypes, however, revealed relatively low
titers.
5.2. Concentration and Purification of Lentiviral Vector Pseudotypes
Typical titers of lentiviral vectors pseudotyped with VSV-G obtained by transient transfection
range from 106 to 107 TU/ml. Increased titers can be achieved by physical concentration
including ultracentrifugation and ultrafiltration of virus-containing cell culture supernatants.
Using a protocol initially designed for the generation of high-titer MLV vector stocks [Burns,
1993], pseudotyped lentiviral particles containing VSV-G have proven to be stable and able
to withstand concentration by ultracentrifugation without significant loss in titer [Bartz,
1996]. This greatly facilitated the generation of highly concentrated vector stocks for in vivo
applications. Lentiviral vectors harboring a wide variety of different GPs have since been
shown to lend themselves to concentration by ultracentrifugation [Reiser, 2000; Kobinger,
2001; Sena-Esteves, 2004].
Concentration protocols based on ultrafiltration were also established for HIV-1-based vectors.
Facile ultrafiltration procedures were developed early on [Reiser, 1996] to concentrate HIV-1
pseudotypes. Good recoveries were observed with HIV-1 particles containing VSV-G or the
amphotropic MLV GP. Improved procedures for concentration by ultrafiltration of other
pseudotypes were subsequently reported [Reiser, 2000; Cui, 2002; Hanawa, 2002; Coleman,
2003; Sena-Esteves, 2004].
Vector production for large-scale in vivo applications that require high-titer stocks is
challenging due to the lack of simple procedures capable of rapidly processing large volumes
of cell culture supernatant. The traditional ultracentrifugation-based approaches are limited in
terms of their capacity to handle large volumes, thus making this procedure extremely tedious.
Centrifugation at low speed overnight has been used to process volumes in excess of one liter
[VandenDriessche, 2002]. However, this low speed approach is time consuming. Thus, there
is an emerging need for quick, reproducible and less laborious procedures that rapidly reduce
the volume of the cell culture supernatant to be processed. Pham et al. [Pham, 2001] have
described a gentle and simple precipitation method to rapidly concentrate pseudotyped
lentiviral vectors involving the co-precipitation of pH-adjusted viral supernatants with calcium
phosphate, low speed centrifugation, and dialysis. Volumes were decreased from 300 ml to 10
ml, with 50-100% recovery of infectious virus. Zhang et al. [Zhang, 2001] have presented an
alternative precipitation method based on poly-L-lysine. Viral supernatants were mixed with
poly-L-lysine, incubated for 30 min at 4°C, and then centrifuged at 10,000 g for 2 h. Recovery
of infectious virus ranged from 26-32% after processing up to 3 liters of cell culture supernatant.
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One problem with the methods outlined above is that cell-derived components are concentrated
along with the vector particles leading to potential immune and inflammation responses
[Baekelandt, 2003]. Thus, ultracentrifugation/ultrafiltration and precipitation approaches
generate rather impure virus preparations and additional steps including chromatography-
based approaches are needed in order to purify the virus of contaminating host cell components.
Methods based on anion exchange chromatography of HIV-1 vectors pseudotyped with VSV-
G have been established [Scherr, 2002; Yamada, 2003]. Schauber et al. [Schauber, 2004]
described a similar procedure for HIV-1 vectors pseudotyped with the baculovirus GP64 GP.
Yields and purity of the virus stocks resulting from these procedure were not reported, but
these approaches may lead to vector stocks of improved purity, increased infectivity and
reduced toxicity.
VSV-G-pseudotyped lentiviral vectors recently entered clinical application. The production,
purification and testing protocols were adapted to GMP standards, and eventually gained FDA
clearance [Lu, 2004;Manilla, 2005].
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Table 1.
Overview of Lentivirus Pseudotypes
Family Genus Species Vector References
Rhabdoviridae Vesiculovirus Vesicular stomatitis virus
(Indiana virus)









Chandipura virus EIAV [Wong, 2004]
Lyssavirus Rabies virus HIV-1 [Mochizuki, 1998]
EIAV [Mitrophanous, 1999]








SIV [Duisit, 2002][Sandrin, 2002]
Togaviridae Alphavirus Ross River virus (RRV) HIV-1 [Kahl, 2004]
FIV [Kang, 2002]
Sindbis virus HIV-1 [Morizono, 2001]




Filoviridae Filovirus Ebola virus Reston HIV-1 [Kobinger, 2001]
Ebola virus Zaire HIV-1 [Kobinger, 2001]
Marburg virus FIV [Sinn, 2003]
Lassa virus HIV-1 [Marzi, 2004]
FIV [Sinn, 2003]
HIV-1 [Marzi, 2004]
Retroviridae Alpharetrovirus Avian leukosis virus (ALV) HIV-1 [Lewis, 2001]














HIV-1 [Hanawa, 2002][Zhang, 2004]
SIV [Sandrin, 2002]
Deltaretrovirus Human T-lymphotropic virus
1 (HTLV-1)
HIV-1 [Landau, 1991]
Spumavirus Human foamy virus HIV-1 [Mochizuki, 1998]
Lentivirus Maedi-visna virus (MVV) HIV-1 [Zeilfelder, 2001]
Coronaviridae Coronavirus SARS-CoV HIV-1 [Hofmann, 2004]
Paramyxoviridae Respirovirus Sendai virus HIV-1 [Kowolik, 2002]







Flaviviridae Hepacivirus Hepatitis C virus (HCV) HIV-1 [Hsu, 2003][Bartosch, 2003]
Orthomyxoviridae Influenzavirus A Influenza virus HIV-1 [Kobinger, 2001][Sandrin,
2002]
Fowl plague virus (FPV) SIV
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Table 2.
Cell and Organ Preferences of Lentivirus Pseudotypes
Target cell/organ Glycoprotein Remarks References
Liver VSV-G Toxicity issues [Park, 2003]
LCMV Non-toxic, less inflammatory [Park, 2003]
RRV Tropism for nonhepatocytes (Kupffer cells) [Kang, 2002]
SeV F [Kowolik, 2002]




SeV F and HN [Sinn, 2003]
JSRV [Kobayashi, 2003]
[Sinn, 2005]
Pancreatic islet cells LCMV Non-toxic [Kobinger, 2004]
CNS VSV-G Targets primarily neurons [Blomer, 1997]
LCMV Targets astrocytes [Miletic, 2004]
Rabies Targets neural progenitor/stem cells [Stein, 2005]
Mokola Retrograde transport from periphery to CNS [Azzouz, 2004a][Azzouz,
2004b]
Retrograde and anterograde transport within
CNS
[Wong, 2004]
Conflicting evidence regarding retrograde and
anterograde transport
[Desmaris, 2001][Watson, 2002]




Mokola Restricted to retinal pigment epithelium [Auricchio, 2001]
Myocytes/muscle Mokola Transduces cardiomyocytes in utero [MacKenzie, 2002]
Ebola Transduces cardiomyocytes in utero [MacKenzie, 2002]
Hematopoietic system RD114 More efficient and less toxic than VSV-G [Sandrin, 2002][Zhang, 2004]
GALV Increased serum stability [Sandrin, 2002]
[Relander, 2005]
Cancer cells GALV Fusogenic glycoprotein [Diaz, 2000]
LCMV Preference for malignant glioma cells [Miletic, 2004][Steffens, 2004]
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